Company Monitoring Page for Biomarin

job ratings (see below graph) for Biomarin

latest headlines for company on cafepharma

BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
Motley Fool
Thu, 01/16/20 - 11:27 pm
Tags:
Biomarin, JPMHC 2020, drug pricing, valrox, hemophilia
BioMarin sets gene therapy sights beyond hemophilia
BioPharma Dive
Mon, 01/13/20 - 11:40 pm
Tags:
Biomarin, hemophilia, gene therapy
These 3 Biotech Stocks Could Be Top Stocks in 2020
Motley Fool
Sun, 01/12/20 - 11:19 pm
Tags:
Biomarin, Iovance, Immunomedics
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
Yahoo/Benzinga
Sat, 01/11/20 - 11:02 pm
Tags:
JPMHC 2020, Bristol-Myers Squibb, Vertex Pharmaceuticals, Biomarin, Regeneron, Biogen, Alexion, Gilead Sciences, Amgen
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
Thu, 12/19/19 - 01:11 pm
Tags:
gene therapy, reimbursement, drug manufacturing, Bristol-Myers Squibb, Pfizer, Biomarin, Sarepta Therapeutics, Gilead Sciences, CAR-T
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Thu, 12/12/19 - 10:52 am
Tags:
Biomarin, hemophilia, hemophilia A, gene therapy, valoctocogene roxaparvovec, uniQure, hemophilia B, etranadez
Here's Why BioMarin Pharmaceutical Leapt 10.2% in November
Motley Fool
Wed, 12/4/19 - 10:19 am
Tags:
Biomarin, R&D, gene therapy, Europe
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
Yahoo/Benzinga
Sun, 10/20/19 - 05:18 pm
Tags:
earnings, Eli Lilly, Alexion, Gilead Sciences, Biomarin, Edwards Lifesciences, Baxter International, Integra LifeSciences, Phathom Pharmaceuticals, IPOs, Foamix, Eton Pharmaceuticals, Melinta Therapeutics, Ligand Pharmaceuticals
BioMarin talks down worries on gene therapy data differences
Biopharma Dive
Tue, 09/10/19 - 11:39 pm
Tags:
Biomarin, gene therapy, hemophilia A, valrox
BioMarin's Roller Coaster Continues
Yahoo/Motley Fool
Tue, 08/6/19 - 11:00 am
Tags:
Biomarin, earnings
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
Fierce Biotech
Fri, 08/2/19 - 10:37 am
Tags:
Biomarin, hemophilia, gene therapy, valoctocogene roxaparvovec, valrox, hemophilia A
Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy
Endpoints
Mon, 07/8/19 - 08:13 pm
Tags:
Biomarin, hemophilia A, gene therapy, FDA, Sangamo, Pfizer
Sangamo backs up early success for hemophilia gene therapy
Biopharma Dive
Sat, 07/6/19 - 01:36 pm
Tags:
Sangamo, gene therapy, hemophilia A, SB-525, Pfizer, Spark Therapeutics, Biomarin
How BioMarin May Revolutionize the Hemophilia Treatment Market
Motley Fool
Tue, 05/28/19 - 11:25 pm
Tags:
Biomarin, gene therapy, hemophilia A, valrox
BioMarin Isn't a "Gene Therapy Company"
Motley Fool
Wed, 05/1/19 - 11:38 pm
Tags:
Biomarin, earnings
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Yahoo/Benzinga
Mon, 04/22/19 - 10:34 am
Tags:
Concert Pharmaceuticals, Horizon Pharma, Edwards Lifesciences, Zimmer Biomet, Genfit, Precision Biosciences, Boston Scientific, AbbVie, Alexion, Bristol-Myers Squibb, Baxter, Biomarin, AtriCure, Biogen, Seattle Genetics, IPOs, earnings
AbbVie, Akcea benefit from latest CHMP recommendations
Biopharma Dive
Sun, 03/3/19 - 07:12 pm
Tags:
Europe, CHMP, AbbVie, Akcea, Biomarin, Sanofi, Pfizer, drug approvals
Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers
Yahoo/Guru Focus
Sun, 02/24/19 - 11:36 pm
Tags:
M&A, Merck, Biogen, Biomarin, Eli Lilly, Bristol-Myers Squibb
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Fierce Pharma
Wed, 02/20/19 - 11:59 am
Tags:
M&A, oncology, neurology, Rare Diseases, Pfizer, Merck, JNJ, Biogen, Biomarin
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
Tags:
clinical trials, Alzheimer's disease, Biogen, Duchenne Muscular Dystrophy, Pfizer, Solid Biosciences, Sarepta Therapeutics, hemophilia A, Biomarin, Multiple Myeloma, Celgene, Bluebird Bio, Amgen, solid tumors, Bristol-Myers Squibb, Nektar Therapeutics, age-related macular degeneration, Regenxbio, SAGE Therapeutics, MorphoSys

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.